Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma

Liver International

Volumn 25, Issue 5, 2005, Pages 954-961

  Pompili, Maurizio ^a   Riccardi, Laura ^a   Covino, Marcello ^a   Barbaro, Brunella ^b   Di Stasi, Carmine ^b   Orefice, Ruggero ^a   Gasbarrini, Giovanni ^a   Rapaccini, Gian Ludovico ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Istituto di Radiologia di Universita Cattolica del Sacro Cuore di Roma   (Italy)

Author keywords

Ablation treatment; Hepatocellular carcinoma; Ultrasound contrast agent

Indexed keywords

ALCOHOL; CONTRAST MEDIUM; SONOVUE; SULFUR HEXAFLUORIDE;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; GRAY SCALE ECHOGRAPHY; HUMAN; LIVER CELL CARCINOMA; LIVER NODULE; MALE; PATIENT MONITORING; RADIOFREQUENCY ABLATION; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; CONTRAST MEDIA; ETHANOL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 26044461656     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01135.x     Document Type: Article

References (35)

1. Bolondi L, Sofia S, Siringo S, et al. Surveillance program for early diagnosis and treatment of hepatocellular carcinoma: a cost effective analysis. Gut 2001; 48: 251-9.
2. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-14.
3. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
4. Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
5. The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994; 74: 2772-80.
6. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long term-results of percutaneous ethanol injection. Radiology 1995; 197: 101-8.
7. Pompili M, Rapaccini G L, de Luca F A, et al. Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Cancer 1997; 79: 1501-8.
8. Lencioni R A, Allgaier H P, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-40.
9. Lin S M, Lin C J, Lin C C, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < 4 cm. Gastroenterology 2004; 127: 1714-23.
10. Llovet J M, Real M I, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
11. Bruix J, Sala M, Llovet J M. Chemoembolisation for hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl. 1): S179-88.
12. Joseph F B, Baumgartner D A, Bernardino M E. Hepatocellular carcinoma: CT appearance after percutaneous ethanol ablation therapy. Radiology 1993; 186: 553-6.
13. Ebara M, Kita K, Sugiura N, et al. Therapeutic effect of percutaneus ethanol injection on small hepatocellular carcinoma: evaluation with CT. Radiology 1995; 195: 371-7.
14. Bartolozzi C, Cioni D, Donati F, et al.. Imaging evaluation of tumor response. In: Bartolozzi C, Lencioni R, eds. Liver Malignancies. Berlin, Heidelsberg: Springer-Verlag, 1999; 467-87.
15. Lencioni R, Caramella D, Bartolozzi C. Hepatocellular carcinoma: use of color Doppler US to evaluate response to treatment with percutaneous ethanol injection. Radiology 1995; 194: 113-8.
16. Bartolozzi C, Lencioni R, Ricci P, et al. Hepatocellular carcinoma treatment with percutaneous ethanol injection: evaluation with contrast-enhanced color Doppler US. Radiology 1998; 209: 387-93.
17. Cedrone A, Pompili M, Sallustio G, et al. Comparison between color power Doppler ultrasound with echo-enhancer and spiral computed tomography in the evaluation of hepatocellular carcinoma vascularization before and after ablation procedures. Am J Gastroenterol 2001; 96: 1854-9.
18. Meloni M F, Godberg S N, Livraghi T, et al. Hepatocellular carcinoma treated with radiofrequency ablation: comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT. Am J Roentgenol 2001; 177: 375-80.
19. Morimoto M, Shirato K, Sugimori K, et al. Contrast-enhanced harmonic gray-scale sonographic-histologic correlation of the therapeutic effects of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Am J Roentgenol 2003; 181: 65-9.
20. Ding H, Kudo M, Onda H, et al. Evaluation of post-treatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT. Radiology 2001; 221: 721-30.
21. Wen Y L, Kudo M, Zheng R Q, et al. Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. Am J Roentgenol 2003; 181: 57-63.
22. Choi D, Lim H K, Lee W J, et al. Early assessment of the therapeutic response to radiofrequency ablation for hepatocellular carcinoma. J Ultrasound Med 2003; 22: 1163-72.
23. Youx J H, Lee J M, Kim C S. Therapeutic response evaluation of malignant hepatic masses treated by interventional procedures with contrast enhanced agent detection imaging. J Ultrasound Med 2003; 22: 911-20.
24. Solbiati L, Topolini M, Cova L, et al. The role of contrast-enhanced ultrasound in the detection of focal liver lesions. Eur Radiol 200 1; 11(Suppl. 3): 15-26.
25. Pugh R, Murray-Lyon I M, Dawson J L, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
26. Bruix J, Sherman M, Llovet J M, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
27. Roche A. Transcatheter arterial chemoembolization of hepatocellular carcinoma. In: Bartolozzi C, Lencioni R, eds. Liver Malignancies. Berlin, Heidelberg: Springer-Verlag, 1999; 255-74.
28. Schneider M. Characteristics of SonoVue. Echocardiography 1999; 16: 743-6.
29. Morel D R, Schwieger I, Hohn L, et al. Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol 2000; 35: 80-5.
30. Bokor D, Chambers J B, Rees P J, et al. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease. Invest Radiol 2001; 36: 104-9.
31. Wilson S R, Burns P N, Nuradali D, et al. Harmonic hepatic US with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma and metastasis. Radiology 2000; 215: 153-61.
32. Befeler A S, Di Bisceglie A M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609-19.
33. Tanaka S, Ioka T, Oshikawa O, et al. Dynamic sonography of hepatic tumors. Am J Roentgeneol 2001; 177: 799-805.
34. Gaiani S, Celli N, Piscaglia F, et al. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 2004; 41: 421-6.
35. Albrecht T, Blomley M, Bolondi L, et al. Guidelines for the use of contrast agents in ultrasound. Ultraschall Med 2004; 25: 249-56.